Abstract 397P
Background
In the Nordics, new treatments have emerged, offering targeted therapies tailored to the specific pathophysiology of breast cancer (BC). These therapies are more effective with fewer side effects than conventional chemotherapy. It's crucial to monitor treatment trends, effectiveness, patient selection, and safety closely. The current study aims to study usability and coverage of real-world data among patients with BC in Norway and Denmark with focus on biomarkers in de novo metastatic BC (mBC).
Methods
BC patients were identified in national administrative registers in Denmark and Norway from January 1, 2015 to December 31, 2020 and followed until death or end of follow-up, i.e., December 31, 2021. Patients were categorized according to stage and biomarker status (hormone receptor (HR) and HER2). Descriptive statistics and one-year survival analyses based on Kaplan-Meier were carried out stratified per country, stage and biomarker status.
Results
In total, 51,641 patients with BC were identified (Denmark: 29,392; Norway=22,249), of which 1,988 (3.8%) had mBC at time of diagnosis (Denmark=946 (3.2%); Norway=1,042 (4.7%)). The age at time of diagnosis of mBC was 68.4 in Denmark and 64.4 in Norway. The number and proportions with HR and HER2 combinations in Denmark and Norway, respectively, were HR+/HER2+ 103 (11%) and 58 (5.6%), HR+/HER2- 608 (64%) and 426 (41%), HR-/HER2+ 51 (5%) and 70 (6.7%), HR-/HER2- (i.e., triple negative) 101 (11%) and 102 (10%), not tested 83 (9%) and 386 (37%). One-year survival was highest among mBC patients with HR+/HER2+ status (Denmark= 0.73 (95% confidence interval (CI), 0.65-0.82); Norway= 0.86 (95% CI, 0.80-0.95)) and lowest among those with triple negative mBC (Denmark= 0.52 (95% CI, 0.44-0.63); Norway=0.51 (95% CI, 0.41-0.62)) as expected.
Conclusions
Results are overall in agreement between the two countries with high coverage. This unique data will later be combined with treatment records and becomes highly valuable for real-world evidence studies of targeted treatments in patients with BC.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Quantify Research.
Funding
Has not received any funding.
Disclosure
J. Liseth Hansen: Other, Institutional, Other, Quantify Research provide consultancy services to pharmaceutical companies and other private and public organizations and institutions: Multiple. M. Johnsen: Other, Institutional, Other, Quantify Research provide consultancy services to pharmaceutical companies and other private and public organizations and institutions: Multiple. F. Fischer: Financial Interests, Institutional, Other, Quantify Research provide consultancy services to pharmaceutical companies and other private and public organizations and institutions: Multiple. O. Ström: Financial Interests, Institutional, Other, Quantify Research provide consultancy services to pharmaceutical companies and other private and public organizations and institutions: Multiple. T. Kopp: Other, Institutional, Other, Quantify Research provide consultancy services to pharmaceutical companies and other private and public organizations and institutions: Multiple.
Resources from the same session
414P - The complex relationship between circulating tumor cells (CTCs) and brain metastases (BMs) in metastatic breast cancer (mBC): A retrospective pooled analysis
Presenter: Brenno Pastò
Session: Poster session 15
415P - Comprehensive liquid biopsy characterization of patients with metastatic inflammatory breast cancer
Presenter: Eleonora Nicolo
Session: Poster session 15
417P - EV derived miR-21 as a promising biomarker for early diagnosis and tumor activity in discrete BC subtypes: The Exobreast project
Presenter: Claudia Omarini
Session: Poster session 15
418P - Concordance of PI3K-AKT pathway alterations between tumor and ctDNA in metastatic breast cancer
Presenter: Charlton Tsai
Session: Poster session 15
419P - Prevalence of gene rearrangement on ctDNA NGS and its targetability in patients with advanced breast cancer
Presenter: Ankur Bahl
Session: Poster session 15
420P - An exosome-based ESR1 monitoring RT-qPCR kit that rapidly and accurately detects acquired resistance variants at ≤ 0.1% frequency in liquid biopsy samples
Presenter: Sarah Statt
Session: Poster session 15
421P - Impact of novel agents in patients with stage IV denovo HR+ve/Her2-ve breast cancer: Results from a real-world dataset
Presenter: Shaheenah Dawood
Session: Poster session 15
422P - Disparities in treatment delays among metastatic breast cancer patients: Insights from nationwide electronic health records, 2011-2022
Presenter: Asal Pilehvari
Session: Poster session 15
423P - Marginalization and factors associated with early mortality among patients diagnosed with de novo metastatic breast cancer in Ontario, Canada
Presenter: Priya Thomas
Session: Poster session 15